Cargando…
Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
Biosimilars are being marketed in India since 2000. Like biologics, biosimilars have a large size, complex structure, and complicated manufacturing process, and they are produced in a living organism. It requires specialized delivery devices for administration and needs tighter temperature control t...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813686/ https://www.ncbi.nlm.nih.gov/pubmed/31571620 http://dx.doi.org/10.4103/jpgm.JPGM_109_19 |